Complex diseases affect us all. Illumina is committed to advancing our understanding of complex diseases and how they will be diagnosed and treated.
Complex diseases result from a combination of genetic and environmental factors, many of which are not understood. These diseases include neurodegenerative, psychiatric, and autoimmune disorders, and others.
The expanding Illumina complex disease product portfolio includes array and next-generation sequencing (NGS) technologies that are helping drive a revolution in complex disease genomics. These solutions deliver high-quality, reproducible results that accelerate research on various complex diseases. These discoveries have the potential to lead to life-changing improvements for patients and their loved ones.
Advancements in genetic disease research have led to better understanding that complex diseases have many genetic components—otherwise known as polygenicity. Polygenic risk scores are a promising area of research for assigning genetic risk to complex diseases. Press play to see how genotyping studies are conducted to develop and validate polygenic risk scores, and how these scores can shape the future understanding of disease risk and mitigation.
Researchers perform genome-wide association studies to identify disease-associated DNA risk loci and develop scores for clinical validation.Read Interview
This review gives a general overview of how genomic technologies and NGS can help in the study of complex diseases, and highlights recent publications featuring Illumina technology.Read Publication Review